This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Farid Sadaka, MD, Mercy Research
ClinicalTrials.gov Identifier:
NCT01319630
First received: March 18, 2011
Last updated: January 24, 2017
Last verified: January 2017
March 18, 2011
January 24, 2017
April 2011
December 2013   (Final data collection date for primary outcome measure)
  • Microcirculatory perfusion and flow variables [ Time Frame: 1 hour after fluid bolus ]
    obtained by Sidestream Dark Field (SDF) microscopy
  • Muscle tissue oxygenation and oxygen consumption [ Time Frame: 1 hour after fluid bolus ]
    using Near Infrared spectroscopy (NIRS)
  • change in microcirculatory and oxygenation variables [ Time Frame: 1 hour after fluid bolus compared to baseline microcirculatory and oxygenation variables ]
    obtained by both SDF and NIRS
Same as current
Complete list of historical versions of study NCT01319630 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients
The Effect of Three Different Fluids(Albumin 5%, Normal Saline, HES 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients Using Sidestream Dark Field (SDF) Microscopy and Near-Infrared Spectroscopy (NIRS) Analysis
Major microvascular blood flow alterations have been documented in patients with severe sepsis. It was also demonstrated that the microcirculation improved in survivors of septic shock but failed to do so in patients dying from acute circulatory failure or with multiple organ failure after shock resolution. Early, effective fluid resuscitation is a key component in the management of patients with severe sepsis and septic shock with the goal of improving tissue perfusion. The best fluid in this early resuscitation phase has been and still is under debate. The aim of this study is to evaluate the effect of Three different Fluids(Albumin 5%, Normal Saline, HES 130 kD) on microcirculation in severe sepsis/septic shock patients using Sidestream Dark Field (SDF) Microscopy and Near-Infrared Spectroscopy (NIRS) analysis.
Not Provided
Observational
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
patients admitted to the Intensive Care Unit with diagnosis of sepsis.
  • Severe Sepsis
  • Septic Shock
  • Microcirculation
  • Device: Sidestream Dark Field (SDF)

    SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.

    After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus.

    Other Name: SDF ((Microscan; Microvision Medical, Amsterdam, the Netherlands)
  • Device: Near Infrared Spectroscopy (NIRS)
    Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
    Other Name: NIRS (InSpectra Model 650, Hutchinson Technology, Hutchinson, Minn.)
  • Normal Saline
    patients with severe sepsis/septic shock randomized to receive 1500 cc of Normal saline bolus as the resuscitation fluid.
    Interventions:
    • Device: Sidestream Dark Field (SDF)
    • Device: Near Infrared Spectroscopy (NIRS)
  • Albumin
    patients with severe sepsis/septic shock randomized to receive 500 cc of Albumin 5% bolus as the resuscitation fluid.
    Interventions:
    • Device: Sidestream Dark Field (SDF)
    • Device: Near Infrared Spectroscopy (NIRS)
  • HES
    patients with severe sepsis/septic shock randomized to receive 500 cc of Hydroxyethyl starch (HES 130kD) bolus as the resuscitation fluid.
    Interventions:
    • Device: Sidestream Dark Field (SDF)
    • Device: Near Infrared Spectroscopy (NIRS)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
April 2016
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients will be enrolled within 24 hrs of onset of severe sepsis/septic shock with an indication for fluid bolus administration.

Exclusion Criteria:

  • Liver cirrhosis
  • shock from other causes
  • Oral injuries (precluding SDF imaging)
  • Severe peripheral vascular disease, dialysis fistula, or mastectomies precluding safe forearm occlusion
  • Age < 18 years
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01319630
11-007
No
Not Provided
Not Provided
Farid Sadaka, MD, Mercy Research
Mercy Research
Not Provided
Principal Investigator: Farid G Sadaka, MD Mercy Hospital St. Louis
Mercy Research
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP